Payment overview · 2025
General Payments
$614.94
28 reported records · 8 companies
Healthcare provider profile · identity verified
Hardeep S Rai, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARROLLTON, TX · NPI 1043324098
Verified facts
What the public records show
CMS Open Payments records show Hardeep S Rai, MD received $614.94 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.09 | 31.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $164.32 | 26.7% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.85 | 10.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.60 | 10.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.78 | 6.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.41 | 6.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.94 | 6.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.95 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $614.94 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $151.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.49 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.26 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.85 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.60 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.78 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.94 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 98 |
| Metformin Hcl | Metformin Hcl | 263 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 77 |
| Lisinopril | Lisinopril | 225 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 61 |
| Gabapentin | Gabapentin | 185 | 59 |
| Simvastatin | Simvastatin | 176 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 37 |
| Losartan Potassium | Losartan Potassium | 163 | 46 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 161 | 60 |
| Glimepiride | Glimepiride | 149 | 44 |
| Carvedilol | Carvedilol | 146 | 44 |
| Azithromycin | Azithromycin | 142 | 105 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 37 |
| Alprazolam | Alprazolam | 115 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 33 |
| Meloxicam | Meloxicam | 111 | 74 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 31 |
| Ozempic | Semaglutide | 101 | 34 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 96 | 30 |
| Mounjaro | Tirzepatide | 92 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 31 |
| Furosemide | Furosemide | 85 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 19 |
| Metformin Hcl Er | Metformin Hcl | 78 | 21 |
| Eliquis | Apixaban | 76 | 16 |
| Tramadol Hcl | Tramadol Hcl | 76 | 23 |
| Montelukast Sodium | Montelukast Sodium | 75 | 21 |
| Donepezil Hcl | Donepezil Hcl | 70 | 26 |
| Prednisone | Prednisone | 69 | 39 |
| Temazepam | Temazepam | 69 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 68 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 17 |
| Potassium Chloride | Potassium Chloride | 65 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 62 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 40 |
| Trazodone Hcl | Trazodone Hcl | 61 | 12 |
| Farxiga | Dapagliflozin Propanediol | 60 | 15 |
| Linzess | Linaclotide | 59 | 21 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 57 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 49 |
| Nifedipine Er | Nifedipine | 56 | 16 |
| Omeprazole | Omeprazole | 53 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 15 |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 29 |
| Mirtazapine | Mirtazapine | 46 | 18 |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Finasteride | Finasteride | 41 | 13 |
| Jardiance | Empagliflozin | 41 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 41 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 14 |
| Famotidine | Famotidine | 31 | 11 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Valsartan | Valsartan | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Humalog | Insulin Lispro | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $614.94 · 28 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error